Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
Journal of Gastroenterology|October 13, 2023
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virusYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.
Scientific Reports|August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabMargherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 29, 2024
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapyYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.
Liver Cancer|May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in LenvatinibMassimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology|March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patientsMargherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology|March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer|November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaFederico Rossari, Toshifumi Tada, Goki Suda, et al.
Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Targeted Oncology|April 30, 2024
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Pageof 15